Article

Effect of oral nirmatrelvir on Long COVID symptoms: a case series

2022-05-05

Abstract excerpt

<title>Abstract</title> <p>As the SARS-CoV-2 pandemic continues to evolve, efforts to understand variability in COVID-19 recovery, as well as the impact of factors including viral variants, vaccine status, and COVID-19 treatment on the development and persistence of Long COVID symptoms have intensified. We report three cases that demonstrate that variability in the timing of nirmatrelvir therapy may be associated...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 76b5e34b-43bd-5e0d-aed3-8452ab359acf
DOI: 10.21203/rs.3.rs-1617822/v2

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Effect of oral nirmatrelvir on Long COVID symptoms: a case seriesDOI 10.21203/rs.3.rs-1617822/v2Read

Oral Nirmatrelvir and Severe Covid-19 Outcomes During the Omicron SurgeSemantic proximity Read

Nirmatrelvir/ritonavir and molnuipiravir in the treatment of mild/moderate COVID-19: results of a real-life studySemantic proximity Read

Manifestaciones orales presentes en pacientes con COVID-19. Revisión sistemática exploratoriaSemantic proximity Read

Oral antivirals for COVID-19 among patients with cancerSemantic proximity Read

Long COVID Treatment No Silver Bullets, Only a Few Bronze BBsSemantic proximity Read

Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single center studySemantic proximity Read

Molnupiravir Use and Severe Covid-19 Outcomes During the Omicron SurgeSemantic proximity Read

Nirmatrelvir, an orally active Mpro inhibitor, is a potent inhibitor of SARS-CoV-2 Variants of ConcernSemantic proximity Read

Nirmatrelvir and ritonavir combination against COVID-19 caused by omicron BA.2.2: A single-center large observational studySemantic proximity Read

Viral Load Rebound in Placebo and Nirmatrelvir-Ritonavir Treated COVID-19 Patients is not Associated with Recurrence of Severe Disease or MutationsSemantic proximity Read

A unifying model to explain high nirmatrelvir therapeutic efficacy against SARS-CoV-2, despite low post-exposure prophylaxis efficacy and frequent viral reboundSemantic proximity Read

Early combination with remdesivir, nirmatrelvir/ritonavir and sotrovimab for the treatment of COVID-19 in immunocompromised hostsSemantic proximity Read